AIM
TRIB

Acrospire Investment Management’s Trinity Biotech TRIB Stock Holding History

Acrospire Investment Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20
Closed -$21K – 2498
2016
Q4 		$21K Buy
+20
New +$20.7K 0.01% 1750

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Acrospire Investment Management's TRIB Position: Q1 2017 in Review

Acrospire Investment Management sold out of Trinity Biotech (TRIB) in Q1 2017, closing a stake of 20 shares — an estimated $21K sold.

Acrospire Investment Management first reported a position in TRIB in Q4 2016 and held it in 1 quarter. The position peaked at $21K in Q4 2016. 67 funds tracked by Wall St. Rank hold TRIB as of Q1 2017.

  • Acrospire Investment Management reported no remaining Trinity Biotech position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 20 Trinity Biotech shares in Q1 2017, an estimated $21K.
  • Acrospire Investment Management first reported a position in Trinity Biotech in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Trinity Biotech position peaked at $21K in Q4 2016.
  • 67 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.